Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
| Autor: | Fabian Termorshuizen, R. van der Griend, S. Wittebol, M. R. Schaafsma, Pieter Sonneveld, Harm Sinnige, P. W. Wijermans, H. M. Lokhorst, Silvia G. R. Verelst, Sonja Zweegman, M. van Marwijk Kooy, Rianne Ammerlaan, C.A. Uyl-de Groot |
|---|---|
| Přispěvatelé: | Hematology, CCA - Quality of life, Erasmus MC other |
| Rok vydání: | 2011 |
| Předmět: |
Melphalan
Male medicine.medical_specialty Constipation Immunology Biochemistry law.invention Quality of life Randomized controlled trial Prednisone law Internal medicine Surveys and Questionnaires otorhinolaryngologic diseases medicine Humans Progression-free survival Prospective Studies Prospective cohort study Antineoplastic Agents Alkylating Glucocorticoids Multiple myeloma Aged Aged 80 and over Models Statistical business.industry Standard treatment Cell Biology social sciences Hematology General Medicine Middle Aged medicine.disease humanities Surgery Thalidomide Treatment Outcome Quality of Life Female medicine.symptom business Multiple Myeloma Immunosuppressive Agents medicine.drug |
| Zdroj: | Verelst, S G R, Termorshuizen, F, Uyl-de Groot, C A, Schaafsma, M R, Ammerlaan, A H M, Wittebol, S, Sinnige, H A M, Zweegman, S, Kooy, M V, van der Griend, R, Lokhorst, H M, Sonneveld, P & Wijermans, P W 2011, ' Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial ', Annals of Hematology, vol. 90, no. 12, pp. 1427-1439 . https://doi.org/10.1007/s00277-011-1224-1 Annals of Hematology, 90(12), 1427-1439. Springer Verlag Annals of Hematology, 90(12), 1427-1439. Springer-Verlag |
| ISSN: | 0939-5555 |
| Popis: | Abstract 2972 Thalidomide (T) with melphalan/prednisone (MPT) was defined as a standard treatment in elderly patients with multiple myeloma (MM) based on 5 randomized trials. Treatment with MPT not only showed improved response rate, significantly better time to response as well as quality of response but also a significant improvement of event free survival (EFS), progression free survival (PFS) and overall survival (OS). In one of these trials, HOVON 49, a prospective Health related – Quality of life (HRQoL) was initiated in order to asses the impact of T on QoL. (Wijermans et al, J Clin Oncol 28:3160-6). Patients aged >65 years with newly diagnosed symptomatic MM were randomized to receive 8 cycles of MP or MPT, followed by T maintenance in MPT arm. 284 patients were included in this HRQoL side study (MP: n=149, MPT: n=135). HRQoL was assessed with the EORTC core QoL Questionnaire (QLQ-C30) and the myeloma-specific module (QLQ-MY24) at baseline and at pre-determined intervals during treatment. Treatment-related toxicity WHO grade 2–4 occurred in 60% of MP and 87% of MP-T treated patients. Most frequently found were neutropenia-related infections, neurotoxicity (mostly T induced peripheral neuropathy) and myelotoxicity. The QLQ-C30 subscales Physical Function (p=0.044) and Constipation (p This prospective study shows that the higher frequency of adverse effects associated with MPT does not translate into a negative effect on HRQoL and that MPT holds a better patient perspective. Disclosures: No relevant conflicts of interest to declare. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink